Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 3, 2013, Pages 686-692

  Spratt, Daniel E ^a   Pei, Xin ^a   Yamada, Josh ^a   Kollmeier, Marisa A ^a   Cox, Brett ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RELAPSE-FREE SURVIVAL; CLINICAL OUTCOME; COMPETING RISKS; GENITOURINARY TOXICITIES; GLEASON SCORES; GROUP-BASED; HIGH DOSE; INTENSITY-MODULATED RADIATION THERAPY; LOCALIZED PROSTATE CANCER; MULTI VARIATE ANALYSIS; RISK CLASSIFICATION; SURVIVAL RATE;

BIOPSY; DISEASES; MULTIVARIANT ANALYSIS; PATIENT MONITORING; PHYSICAL THERAPY; RADIOTHERAPY;

TOXICITY;

ANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMORRHAGIC CYSTITIS; HIGH RISK POPULATION; HUMAN; IMPOTENCE; INTENSITY MODULATED RADIATION THERAPY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER SPECIFIC MORTALITY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION HAZARD; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM STENOSIS; RISK FACTOR; SEXUAL FUNCTION; URETHRA STRICTURE; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; UROGENITAL TRACT TOXICITY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PENILE ERECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 84873307700     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.05.023     Document Type: Article

References (20)

1. R.K. Rhamy, S.K. Wilson, and W.L. Caldwell Biopsy-proved tumor following definitive irradiation for resectable carcinoma of the prostate J Urol 107 1972 627 630
2. M.J. Zelefsky, V.E. Reuter, and Z. Fuks Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer J Urol 179 2008 1368 1373
3. B.M. Dubray, V. Beckendorf, and S. Guerif Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU20503/NCT00104741) J Clin Oncol 29 suppl15 2011 4521
4. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
5. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
6. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
7. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
8. V. Beckendorf, S. Guerif, and E. Le Prise The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity Int J Radiat Oncol Biol Phys 60 2004 1056 1065
9. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
10. G.E. Hanks, A.L. Hanlon, and B. Epstein Dose response in prostate cancer with 8-12 years'follow-up Int J Radiat Oncol Biol Phys 54 2002 427 435
11. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
12. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
13. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881
14. T.N. Eade, A.L. Hanlon, and E.M. Horwitz What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68 2007 682 689
15. N. Pahlajani, K.J. Ruth, and M.K. Buyyounouski Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer Int J Radiat Oncol Biol Phys 82 2012 1949 1956
16. S. Levegrun, A. Jackson, and M.J. Zelefsky Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Radiother Oncol 63 2002 11 26
17. R.G. Stock, N.N. Stone, and A. Tabert A dose-response study for I-125 prostate implants Int J Radiat Oncol Biol Phys 41 1998 101 108
18. M.J. Zelefsky, Z. Fuks, and L. Happersett Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer Radiother Oncol 55 2000 241 249
19. J.M. Michalski, K. Bae, and M. Roach Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study Int J Radiat Oncol Biol Phys 76 2010 14 22
20. M.J. Zelefsky, M. Kollmeier, and B. Cox Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer Int J Radiat Oncol Biol Phys 2012 Feb 11 [Epub ahead of print]